Regarding the involvement of the MAPKs’ signaling pathways in cancer, it is known that approximately 50% of melanomas exhibit mutations in the BRAF oncogene, leading to constitutive activation of the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2) pathway and uncontrolled proliferation [27]. The gene discussed is MAPK3; the disease is melanoma.